Cite
HARVARD Citation
Mateos, M. et al. (2019). Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet. 6 (9), pp. e459-e469. [Online].